SAVA - Cassava Sciences Q3 costs rise amid late-stage Alzheimer's program
2023-11-07 10:08:44 ET
More on Cassava Sciences
- Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease
- Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
- Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims
- Cassava Sciences GAAP EPS of -$0.61 beats by $0.29
- Cassava Sciences fully enrolls Phase 3 program for Alzheimer’s candidate
For further details see:
Cassava Sciences Q3 costs rise amid late-stage Alzheimer’s program